Tessera Therapeutics Stock

Tessera Therapeutics is a biotechnology company that focuses on a new category of genetic medicines.

Sign up today and learn more about Tessera Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Tessera Therapeutics Stock

Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.


Funding History

May 2020$2.7M
January 2021$230M
April 2022$300M


Co-Founder & Chief Scientific Officer

Jacob Rubens

President and CFO

Howard Liang

Chief Data Officer

Iain McFadyen

Co-Founder, Chief Executive Officer & Board member

Geoffrey von Maltzahn


EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: